| Literature DB >> 31572473 |
Aristotelis Perrakis1,2, Nikolaos Vassos1, Klaus Weber1, Klaus E Matzel1, Konstantinos Papadopoulos3, Georgios Koukis3, Evangelos Perrakis3, Roland S Croner1,2, Werner Hohenberger1.
Abstract
INTRODUCTION: Complete mesocolic excision (CME) is generally accepted as state of the art in colon cancer surgery. However, the long-term impact of CME has not been systematically examined. Therefore cohort studies might be a possible way to clarify any differences between conventional resections and CME. Following bilateral cooperation between the Department of Surgery/University Hospital of Erlangen and the 1st Surgical Department of the General Hospital of Nikaia/Piraeus, including teaching activities for introduction of CME, a cohort study was performed, considering surgical quality criteria and clinical outcome.Entities:
Keywords: central vascular ligation; colon carcinoma; complete mesocolic excision; lymph node; surgery
Year: 2018 PMID: 31572473 PMCID: PMC6764310 DOI: 10.5114/aoms.2018.80040
Source DB: PubMed Journal: Arch Med Sci ISSN: 1734-1922 Impact factor: 3.318
Figure 1Specimen after right hemicolectomy (the upper clamp shows the site of the tumor; the 2 clamps at the bottom show the marking of the CVL)
Figure 2Specimen after sigmoid resection for cancer (the upper clamp shows the site of the tumor and the 2 clamps on the other side the supplying vessels)
Clinical and histopathological characteristics in CME (n = 31) and non-CME (n = 35) group
| Parameter | CME group ( | Non-CME group ( | |
|---|---|---|---|
| Age [years] | 75 (55–84) | 69 (29–89) | 0.024 |
| Gender: | |||
| Male | 14 (45) | 17 (49) | 0.167 |
| Female | 17 (55) | 18 (51) | 0.158 |
| ASA classification: | |||
| ASA I | 0 (0) | 6 (17) | < 0.001 |
| ASA II | 14 (45) | 11 (32) | 0.018 |
| ASA III | 17 (58) | 18 (51) | 0.658 |
| Site of tumor: | |||
| Caecum | 6 (19) | 9 (26) | 0.081 |
| Ascending colon | 10 (32) | 6 (17) | 0.034 |
| Transverse colon | 2 (7) | 5 (13) | 0.146 |
| Hepatic flexure | 2 (7) | 3 (9) | 0.473 |
| Splenic flexure | 0 (0) | 1 (3) | < 0.001 |
| Descending colon | 0 (0) | 1 (3) | < 0.001 |
| Sigmoid colon | 11 (35) | 10 (29) | 0.537 |
| Surgical procedure: | |||
| Right hemicolectomy | 16 (52) | 15 (42) | 0.586 |
| Sigmoidectomy | 11 (35) | 10 (29) | 0.537 |
| Subtotal colectomy | 2 (7) | 2 (6) | 0.894 |
| Extended right hemicolectomy | 2 (7) | 8 (23) | 0.034 |
| Type of surgery: | |||
| Elective | 24 (77) | 27 (77) | 0.769 |
| Emergency | 7 (23) | 8 (23) | 0.128 |
| Tumor stage: | |||
| pT2 | 9 (29) | 5 (14) | 0.027 |
| pT3 | 18 (58) | 27 (77) | 0.015 |
| pT4 | 4 (13) | 3 (9) | 0.489 |
| pN0 | 15 (48) | 21 (60) | 0.137 |
| pN+: | 16 (52) | 14 (40) | 0.494 |
| pN1 | 9 (29) | 7 (20) | 0.149 |
| pN2 | 7 (23) | 7 (20) | 0.892 |
| M0 | 27 (87) | 32 (91) | 0.917 |
| M1 | 4 (13) | 3 (9) | 0.649 |
| Hepatic | 4 | 2 (6) | 0.337 |
| Peritoneal | 1 (3) | < 0.001 | |
| Lymph node yield and ratio: | |||
| Lymph node yield | 29.6 | 17.85 | < 0.001 |
| LNR (UICC stage III) | 0.095 | 0.18 | 0.01 |
| LNR (overall) | 0.12 | 0.24 | < 0.001 |
| UICC stage: | |||
| I | 9 (29) | 5 (14) | 0.027 |
| II | 6 (19) | 16 (46) | < 0.001 |
| III | 12 (39) | 11 (31) | 0.559 |
| IV | 4 (13) | 3 (9) | 0.489 |
| Tumor grade: | |||
| Well-differentiated (G1) | 0 (0) | 0 (0) | NS |
| Moderately differentiated (G2) | 21 (68) | 30 (86) | < 0.001 |
| Poorly differentiated (G3) | 10 (32) | 5 (14) | < 0.001 |
Figure 3Dissection of mesocolon from mesopancreas over the head of the pancreas (white arrow shows the duodenum)
Figure 4Central vascular ligation (CVL) (white arrow shows the CVL of the ileocolic artery, green arrow shows the central ligation of the ileocolic vein, blue arrow shows the superior mesenteric artery (AMS))
Figure 5Infrapancreatic lymph node region and dissection (white arrow shows the duodenum, blue arrow shows the head of the pancreas, green shows the superior mesenteric vein (VMS), red arrow shows the CVL)
Complications in CME (n = 31) and non-CME (n = 35) group
| Parameter | CME group ( | Non-CME group ( | |
|---|---|---|---|
| None | 23 (74) | 18 (51) | 0.018 |
| Surgical complications | 5 (16) | 10 (29) | 0.021 |
| Anastomotic leakage | 3 (9) | 5 (14) | 0.134 |
| Sepsis | 2 (6) | 6 (17) | 0.034 |
| Lymph fistula | 1 (3) | 0 (0) | < 0.001 |
| Impairment of micturition | 1 (3) | 0 (0) | < 0.001 |
| Hematoma | 2 (6) | 3 (9) | 0.473 |
| Wound infection | 2 (6) | 5 (14) | 0.146 |
| Nonsurgical complications: | 3 (10) | 7 (20) | 0.032 |
| Cardiological | 2 (6) | 4 (12) | 0.065 |
| Renal failure | 1 (2) | 3 (9) | 0.164 |
| In-hospital mortality | 1 (2) | 4 (11) | 0.147 |
More complications in 1 patient possible.
Follow-up data in CME (n = 31) and non-CME (n = 35) group
| Parameter | CME group ( | Non-CME group ( | |
|---|---|---|---|
| Median follow-up [months] | 45 (36–48) | 78 (58–108) | |
| Local recurrence | 0/31 (0) | 5/35 (14.3) | 0.012 |
| Recurrence-free survival | 31/31 (100) | 30/35 (85) | 0.044 |
| Metastases: | |||
| Synchronous | 4 | 3 | |
| Metachronous | 3 | 3 | |
| Metastasis-free survival (patients with synchronous metastases excluded) | 24/27 (89) | 29/32 (91) | 0.278 |
| Overall survival (patients with synchronous metastases included) | 29/31 (94) | 24/35 (69) | 0.021 |